IVD company Virtue Diagnostics has closed a USD100 million Series B funding round jointly led by Sequoia China and Morningside Ventures.
ORIZA Holdings also participated in the round alongside existing investors Lilly Asia Ventures and PerkinElmer Ventures. HAOYUE Capital acted as the exclusive financial advisor.
Virtue Diagnostics is a global, platform-based IVD (In Vitro Diagnostic) company focusing on providing affordable clinical solutions at all disease stages including very early screening, initial diagnosis, treatment monitoring and minimal residual disease management.
